Teclistamab-daratumumab combination wins CHMP backing
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion on extending the indication for teclistamab, combined with subcutaneous daratumumab, for treating patients with relapsed/refractory multiple myeloma (RRMM) as early as first relapse. The opinion was supported by the 83.4% reduction in the risk of disease progression or death in patients who received the combination treatment, compared to standard of care, in the phase 3 MajesTEC-3 study. Teclistamab-daratumumab combination therapy gained FDA approval in RRMM after ≥1 prior therapy in March 2026.

Draft guidelines on AL amyloidosis from ASH open for public comment
The American Society of Hematology (ASH) is seeking public comment on draft guideline recommendations for management of AL amyloidosis. The public comment period is open until July 7, 2026. Details are available here.

Pooled analysis supports feasibility of teclistamab-based induction in NDMM
A prespecified pooled analysis of data from the phase 2 MajestTEC-5 study showed a minimal residual disease (MRD)-negative complete response (CR) rate of 91.8% in transplant-eligible patients with newly diagnosed MM (NDMM) who received teclistamab-daratumumab-lenalidomide, with/without bortezomib, as induction therapy. The findings, reported in Nature Medicine, span the induction and autologous stem cell transplant treatment phases, prior to maintenance.

Review highlights potential of patient-derived organoids in hematologic malignancies
Patient-derived organoids (PDOs) are miniature three-dimensional tissue models generated by culturing tumor cells obtained from biopsy/surgical specimens or biologic fluids, including blood samples. A report published in Trends in Cancer summarizes the current state of science in hematologic PDOs, including those modeling the complex marrow microenvironment in MM.

Cilta-cel demonstrates real-world efficacy in RRMM
According to a real-world analysis that included 120 patients with RRMM who received ciltacabtagene autoleucel after 1-3 prior lines of treatment, the overall response rate (ORR) was 98%, with ORR ranging from 95% to 100% across different bridging therapies, including talquetamab. These results were published in Oncology and Therapy.

Mechanistic modeling approach may aid clinical trial design, optimal dosing
In an article published in Clinical Pharmacology and Therapeutics, researchers outline the development of a mechanism-informed quantitative systems pharmacology (QSP)-based computational model that integrates baseline and dynamic disease features and CAR T-cell characteristics. The QSP model recapitulated pharmacokinetic and biomarker response data for CAR-T recipients. QSP models may help predict response outcomes and optimize trial design and dosing regimens, the authors concluded.